Docetaxel Pharmacokinetics with Pre- and Post-Dialysis Administration in a Hemodyalized Patient

Background: Docetaxel has a proven significant activity against breast, non-small cell lung, ovarian, head and neck, and hormone refractory prostate cancer. Preclinical pharmacokinetic studies have shown that hepatobiliary extraction is the major route of elimination. We conducted this study to eluc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chemotherapy (Basel) 2006-01, Vol.52 (3), p.147-150
Hauptverfasser: Mencoboni, M., Olivieri, R., Vannozzi, M.O., Schettini, G., Viazzi, F., Ghio, R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 150
container_issue 3
container_start_page 147
container_title Chemotherapy (Basel)
container_volume 52
creator Mencoboni, M.
Olivieri, R.
Vannozzi, M.O.
Schettini, G.
Viazzi, F.
Ghio, R.
description Background: Docetaxel has a proven significant activity against breast, non-small cell lung, ovarian, head and neck, and hormone refractory prostate cancer. Preclinical pharmacokinetic studies have shown that hepatobiliary extraction is the major route of elimination. We conducted this study to elucidate the feasibility and safety of the use of docetaxel in hemodialysis patients. Patient and Methods: In a 72-year-old hormone refractory prostate cancer patient on hemodialysis for diabetic nephropathy for 3 years, a first dose (35 mg/m 2 iv) of docetaxel was completed 30 min before starting dialysis, while a second dose was administered 30 min after completion of a different hemodialysis session. Pharmacokinetic analysis was performed following both infusions. Results: No apparent differences could be seen in the plasma concentration-time curves of docetaxel administered before or after dialysis. The patient experienced no significant toxicityafter either administration of docetaxel. Conclusions: Docetaxel is safe in dialysis patients and does not require dose reduction. Dialysis does not remove this drug from blood.
doi_str_mv 10.1159/000092903
format Article
fullrecord <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_17778916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1038336411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-b9e4ab329c9b3630f0cb9c377c2798661a8272025b5282965b9a2d0571414f9b3</originalsourceid><addsrcrecordid>eNpF0M9LwzAUB_Agis7pwbMgQfDgoZofbdIch1MnCO6g5_KaphrXHzPJ0PnXG2nRXB5JPnkvfBE6oeSK0kxdk7gUU4TvoAlNGU2UVOkumvweJ5xm8gAdev8et1xwuo8OqBBcZFxOUDHvtQnwZRq8fAPXgu5XtjPBao8_bXjDS2cSDF2Fl70PydxCs_XW41nV2s764CDYvsO2w4AXpu2rLTT220QeL0wXjtBeDY03x2Odope72-ebRfL4dP9wM3tMNBckJKUyKZScKa3K-EdSE10qzaXUTKpcCAo5k4ywrMxYzpTISgWsIpmkKU3r-GaKzoe-a9d_bIwPxXu_cV0cWTDGmcxELFN0OSDteu-dqYu1sy24bUFJ8Ztk8ZdktGdjw03ZmupfjtFFcDEC8Bqa2kGnrf93UspcURHd6eBW4F6N-wPDmB-5jIIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223275622</pqid></control><display><type>article</type><title>Docetaxel Pharmacokinetics with Pre- and Post-Dialysis Administration in a Hemodyalized Patient</title><source>MEDLINE</source><source>Karger Journals</source><creator>Mencoboni, M. ; Olivieri, R. ; Vannozzi, M.O. ; Schettini, G. ; Viazzi, F. ; Ghio, R.</creator><creatorcontrib>Mencoboni, M. ; Olivieri, R. ; Vannozzi, M.O. ; Schettini, G. ; Viazzi, F. ; Ghio, R.</creatorcontrib><description>Background: Docetaxel has a proven significant activity against breast, non-small cell lung, ovarian, head and neck, and hormone refractory prostate cancer. Preclinical pharmacokinetic studies have shown that hepatobiliary extraction is the major route of elimination. We conducted this study to elucidate the feasibility and safety of the use of docetaxel in hemodialysis patients. Patient and Methods: In a 72-year-old hormone refractory prostate cancer patient on hemodialysis for diabetic nephropathy for 3 years, a first dose (35 mg/m 2 iv) of docetaxel was completed 30 min before starting dialysis, while a second dose was administered 30 min after completion of a different hemodialysis session. Pharmacokinetic analysis was performed following both infusions. Results: No apparent differences could be seen in the plasma concentration-time curves of docetaxel administered before or after dialysis. The patient experienced no significant toxicityafter either administration of docetaxel. Conclusions: Docetaxel is safe in dialysis patients and does not require dose reduction. Dialysis does not remove this drug from blood.</description><identifier>ISSN: 0009-3157</identifier><identifier>EISSN: 1421-9794</identifier><identifier>DOI: 10.1159/000092903</identifier><identifier>PMID: 16636537</identifier><identifier>CODEN: CHTHBK</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Aged ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - administration &amp; dosage ; Antineoplastic Agents, Phytogenic - pharmacokinetics ; Biological and medical sciences ; Case Report ; Chemotherapy ; Chromatography, High Pressure Liquid ; Diabetic Nephropathies - complications ; Diabetic Nephropathies - therapy ; Drug Administration Schedule ; Drug therapy ; Hemodialysis ; Hemodialysis Solutions - analysis ; Humans ; Male ; Medical sciences ; Patients ; Pharmacology ; Pharmacology. Drug treatments ; Prostate cancer ; Prostatic Neoplasms - complications ; Prostatic Neoplasms - metabolism ; Renal Dialysis ; Taxoids - administration &amp; dosage ; Taxoids - pharmacokinetics</subject><ispartof>Chemotherapy (Basel), 2006-01, Vol.52 (3), p.147-150</ispartof><rights>2006 S. Karger AG, Basel</rights><rights>2006 INIST-CNRS</rights><rights>Copyright 2006 S. Karger AG, Basel.</rights><rights>Copyright (c) 2006 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-b9e4ab329c9b3630f0cb9c377c2798661a8272025b5282965b9a2d0571414f9b3</citedby><cites>FETCH-LOGICAL-c360t-b9e4ab329c9b3630f0cb9c377c2798661a8272025b5282965b9a2d0571414f9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17778916$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16636537$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mencoboni, M.</creatorcontrib><creatorcontrib>Olivieri, R.</creatorcontrib><creatorcontrib>Vannozzi, M.O.</creatorcontrib><creatorcontrib>Schettini, G.</creatorcontrib><creatorcontrib>Viazzi, F.</creatorcontrib><creatorcontrib>Ghio, R.</creatorcontrib><title>Docetaxel Pharmacokinetics with Pre- and Post-Dialysis Administration in a Hemodyalized Patient</title><title>Chemotherapy (Basel)</title><addtitle>Chemotherapy</addtitle><description>Background: Docetaxel has a proven significant activity against breast, non-small cell lung, ovarian, head and neck, and hormone refractory prostate cancer. Preclinical pharmacokinetic studies have shown that hepatobiliary extraction is the major route of elimination. We conducted this study to elucidate the feasibility and safety of the use of docetaxel in hemodialysis patients. Patient and Methods: In a 72-year-old hormone refractory prostate cancer patient on hemodialysis for diabetic nephropathy for 3 years, a first dose (35 mg/m 2 iv) of docetaxel was completed 30 min before starting dialysis, while a second dose was administered 30 min after completion of a different hemodialysis session. Pharmacokinetic analysis was performed following both infusions. Results: No apparent differences could be seen in the plasma concentration-time curves of docetaxel administered before or after dialysis. The patient experienced no significant toxicityafter either administration of docetaxel. Conclusions: Docetaxel is safe in dialysis patients and does not require dose reduction. Dialysis does not remove this drug from blood.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - administration &amp; dosage</subject><subject>Antineoplastic Agents, Phytogenic - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Case Report</subject><subject>Chemotherapy</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Diabetic Nephropathies - complications</subject><subject>Diabetic Nephropathies - therapy</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Hemodialysis</subject><subject>Hemodialysis Solutions - analysis</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Patients</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - complications</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Renal Dialysis</subject><subject>Taxoids - administration &amp; dosage</subject><subject>Taxoids - pharmacokinetics</subject><issn>0009-3157</issn><issn>1421-9794</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpF0M9LwzAUB_Agis7pwbMgQfDgoZofbdIch1MnCO6g5_KaphrXHzPJ0PnXG2nRXB5JPnkvfBE6oeSK0kxdk7gUU4TvoAlNGU2UVOkumvweJ5xm8gAdev8et1xwuo8OqBBcZFxOUDHvtQnwZRq8fAPXgu5XtjPBao8_bXjDS2cSDF2Fl70PydxCs_XW41nV2s764CDYvsO2w4AXpu2rLTT220QeL0wXjtBeDY03x2Odope72-ebRfL4dP9wM3tMNBckJKUyKZScKa3K-EdSE10qzaXUTKpcCAo5k4ywrMxYzpTISgWsIpmkKU3r-GaKzoe-a9d_bIwPxXu_cV0cWTDGmcxELFN0OSDteu-dqYu1sy24bUFJ8Ztk8ZdktGdjw03ZmupfjtFFcDEC8Bqa2kGnrf93UspcURHd6eBW4F6N-wPDmB-5jIIQ</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>Mencoboni, M.</creator><creator>Olivieri, R.</creator><creator>Vannozzi, M.O.</creator><creator>Schettini, G.</creator><creator>Viazzi, F.</creator><creator>Ghio, R.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20060101</creationdate><title>Docetaxel Pharmacokinetics with Pre- and Post-Dialysis Administration in a Hemodyalized Patient</title><author>Mencoboni, M. ; Olivieri, R. ; Vannozzi, M.O. ; Schettini, G. ; Viazzi, F. ; Ghio, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-b9e4ab329c9b3630f0cb9c377c2798661a8272025b5282965b9a2d0571414f9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - administration &amp; dosage</topic><topic>Antineoplastic Agents, Phytogenic - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Case Report</topic><topic>Chemotherapy</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Diabetic Nephropathies - complications</topic><topic>Diabetic Nephropathies - therapy</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Hemodialysis</topic><topic>Hemodialysis Solutions - analysis</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Patients</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - complications</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Renal Dialysis</topic><topic>Taxoids - administration &amp; dosage</topic><topic>Taxoids - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mencoboni, M.</creatorcontrib><creatorcontrib>Olivieri, R.</creatorcontrib><creatorcontrib>Vannozzi, M.O.</creatorcontrib><creatorcontrib>Schettini, G.</creatorcontrib><creatorcontrib>Viazzi, F.</creatorcontrib><creatorcontrib>Ghio, R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Chemotherapy (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mencoboni, M.</au><au>Olivieri, R.</au><au>Vannozzi, M.O.</au><au>Schettini, G.</au><au>Viazzi, F.</au><au>Ghio, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Docetaxel Pharmacokinetics with Pre- and Post-Dialysis Administration in a Hemodyalized Patient</atitle><jtitle>Chemotherapy (Basel)</jtitle><addtitle>Chemotherapy</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>52</volume><issue>3</issue><spage>147</spage><epage>150</epage><pages>147-150</pages><issn>0009-3157</issn><eissn>1421-9794</eissn><coden>CHTHBK</coden><abstract>Background: Docetaxel has a proven significant activity against breast, non-small cell lung, ovarian, head and neck, and hormone refractory prostate cancer. Preclinical pharmacokinetic studies have shown that hepatobiliary extraction is the major route of elimination. We conducted this study to elucidate the feasibility and safety of the use of docetaxel in hemodialysis patients. Patient and Methods: In a 72-year-old hormone refractory prostate cancer patient on hemodialysis for diabetic nephropathy for 3 years, a first dose (35 mg/m 2 iv) of docetaxel was completed 30 min before starting dialysis, while a second dose was administered 30 min after completion of a different hemodialysis session. Pharmacokinetic analysis was performed following both infusions. Results: No apparent differences could be seen in the plasma concentration-time curves of docetaxel administered before or after dialysis. The patient experienced no significant toxicityafter either administration of docetaxel. Conclusions: Docetaxel is safe in dialysis patients and does not require dose reduction. Dialysis does not remove this drug from blood.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>16636537</pmid><doi>10.1159/000092903</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-3157
ispartof Chemotherapy (Basel), 2006-01, Vol.52 (3), p.147-150
issn 0009-3157
1421-9794
language eng
recordid cdi_pascalfrancis_primary_17778916
source MEDLINE; Karger Journals
subjects Aged
Antineoplastic agents
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - pharmacokinetics
Biological and medical sciences
Case Report
Chemotherapy
Chromatography, High Pressure Liquid
Diabetic Nephropathies - complications
Diabetic Nephropathies - therapy
Drug Administration Schedule
Drug therapy
Hemodialysis
Hemodialysis Solutions - analysis
Humans
Male
Medical sciences
Patients
Pharmacology
Pharmacology. Drug treatments
Prostate cancer
Prostatic Neoplasms - complications
Prostatic Neoplasms - metabolism
Renal Dialysis
Taxoids - administration & dosage
Taxoids - pharmacokinetics
title Docetaxel Pharmacokinetics with Pre- and Post-Dialysis Administration in a Hemodyalized Patient
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A22%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Docetaxel%20Pharmacokinetics%20with%20Pre-%20and%20Post-Dialysis%20Administration%20in%20a%20Hemodyalized%20Patient&rft.jtitle=Chemotherapy%20(Basel)&rft.au=Mencoboni,%20M.&rft.date=2006-01-01&rft.volume=52&rft.issue=3&rft.spage=147&rft.epage=150&rft.pages=147-150&rft.issn=0009-3157&rft.eissn=1421-9794&rft.coden=CHTHBK&rft_id=info:doi/10.1159/000092903&rft_dat=%3Cproquest_pasca%3E1038336411%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223275622&rft_id=info:pmid/16636537&rfr_iscdi=true